BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate...
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen, Denmark: EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients. NEW...
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as international standards amid projected global market growth to USD 6.3 billion by 3034 SKBS continues strategic R&D to enhance global vaccine competitiveness of its vaccine pipelines ...
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Ascletis...
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech’s Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally...
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced biliary tract cancer (BTC) (AK112-309/HARMONi-GI1). This Phase III trial is being conducted in China....
Heartbeats: 230,000 Views for Dr. Kiat’s Everyday Lunch – A Viral Lesson That Science Has No Borders
SYDNEY, Sept. 2, 2025 /PRNewswire/ -- A humble lunch video from world-renowned cardiologist Dr. Hosen Kiat has captured more than 230,000 views on Chinese social media Little Red Book. Shared as part of his new digital wellness initiative with Heartbeats, the "real-style" post featured nothing more than a cup of black coffee, a vegetarian sandwich, steamed vegetables, and mushrooms -...
SteriLance Safety Lancets Adopted Across Thailand’s Public-Hospital Channels
BANGKOK, Sept. 2, 2025 /PRNewswire/ -- SteriLance Medical announced that its safety lancet portfolio — PRESS PLUS, IMPRESS and LITE3 — has been adopted within Thailand's public-hospital channels following a tender awarded by a nationally recognized humanitarian organization. Supply and post-market support are being delivered through an authorized local distributor holding Thai FDA registrations. ...
LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The partnership covers a late-stage Phase...
AMI Pharm’s AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction
AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction SEOUL, South Korea, Sept....
